Advertisement

Topics

Sage’s brexanolone meets primary endpoints in phase 3 postpartum depression trials

03:01 EST 10 Nov 2017 | Pharmaceutical Business Review

Sage Therapeutics has reported positive top-line results from two phase 3 clinical trials with its i.v. formulation of brexanolone (USAN; formerly SAGE-547); Study 202B in severe postpartum depression (PPD) and Study 202C in moderate PPD.

Original Article: Sage’s brexanolone meets primary endpoints in phase 3 postpartum depression trials

NEXT ARTICLE

More From BioPortfolio on "Sage’s brexanolone meets primary endpoints in phase 3 postpartum depression trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...